Angion Biomedica

Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease.

Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open heart surgery using cardiopulmonary bypass. Angion Biomedica was founded in 1998 and is based in Uniondale, New York.